Institut Català de la Salut
[Nielsen TL, Hornsyld TM, Vissing J, Krag TO] Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. [Pinós T] Grup de Recerca de Patologia Neuromuscular i Mitocondrial, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. [Brolin C] Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
Vall d'Hebron Barcelona Hospital Campus
2023-01-11T13:17:34Z
2023-01-11T13:17:34Z
2022-01-28
Hepatocyte growth factor; Leukemia inhibitory factor; Muscular regeneration
Factor de crecimiento de los hepatocitos; Factor inhibidor de la leucemia; Regeneración muscular
Factor de creixement dels hepatòcits; Factor inhibidor de la leucèmia; Regeneració muscular
Muscular dystrophies constitute a broad group of genetic disorders leading to muscle wasting. We have previously demonstrated that treating a muscular atrophy mouse model with growth factors resulted in increased muscle mass. In the present study, we treated the Duchenne mouse model mdx for 12 weeks with myogenic growth factors peri- and post-onset of muscular degeneration to explore the effects in the oxidative muscle soleus and the glycolytic muscle extensor digitorum longus (EDL). We found no overall beneficial effect in the peri-onset group at the conclusion of the study. In the post-onset group, the functional improvement by means of electrophysiological examinations ex vivo was mostly confined to the soleus. EDL benefitted from the treatment on a molecular level but did not improve functionally. Histopathology revealed signs of inflammation at the end of treatment. In conclusion, the growth factor cocktail failed to improve the mdx on a functional level.
This work was supported by grants from the Lundbeck Foundation (Grant No. R140-2013-13370 to J.V. and T.O.K.), Novo Nordisk Foundation (Grant No. 8091 to J.V. and T.O.K.), AP Møller Foundations (Grant No. 13-222 to T.O.K.), Instituto de Salud Carlos III y Fondos FEDER (FIS Project PI19/01313 to T.P.), and Augustinus Foundation (Grant No. 13-4153 to T.O.K.). None of the funding sources had any involvement in the study, data evaluation, or authoring of the manuscript.
Article
Published version
English
Distròfia muscular - Aspectes genètics; Ratolins; Factors de creixement - Ús terapèutic; DISEASES::Nervous System Diseases::Neuromuscular Diseases::Muscular Diseases::Muscular Disorders, Atrophic::Muscular Dystrophies; Other subheadings::Other subheadings::Other subheadings::/genetics; ORGANISMS::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Eutheria::Rodentia::Muridae::Murinae::Mice; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Hepatocyte Growth Factor; Other subheadings::Other subheadings::/therapeutic use; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades neuromusculares::enfermedades musculares::trastornos musculares atróficos::distrofias musculares; Otros calificadores::Otros calificadores::Otros calificadores::/genética; ORGANISMOS::Eukaryota::animales::Chordata::vertebrados::mamíferos::Eutheria::Rodentia::Muridae::Murinae::ratones; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intercelular::citocinas::factor de crecimiento del hepatocito; Otros calificadores::Otros calificadores::/uso terapéutico
MDPI
Biomedicines;10(2)
https://doi.org/10.3390/biomedicines10020304
info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01313
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]